Home Run

On occasion, an opportunity presents itself to swing for the fences, so to speak. Dendreon Corporation did just that. Earlier this week it received approval for its prostate cancer therapy drug, Provenge. As noted earlier in this blog, we bought 10 May 40 calls @ 5.90 each on April 9th. Today, we sell @ 15.85. Excluding commissions, $ 5,900.00 invested is now $ 15,850.00.

A Couple Months

Sadly I have not had the time to dedicate to this blog as I had hoped. I'll still staty with it for now as I do enjoy the little time I get on here.